Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The drug will be available in 600 hospitals and 105 DTPs
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Subscribe To Our Newsletter & Stay Updated
